Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...
Fourth-Quarter Revenue: $167.5 million. Full-Year Revenue: $634.4 million. Revenue Growth Ex-COVID (Q4): 13% year-over-year. Adjusted Gross Margin (Q4): 50.7%. Adjusted Operating Margin (Q4): 14.9%.
A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 11.4% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...
Repligen (NASDAQ:RGEN) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results